# Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

> **NCT05435053** · PHASE2 · TERMINATED · sponsor: **Ismail Gögenur** · enrollment: 9 (actual)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** Nivolumab
- **DEVICE:** Irreversible electroporation (IRE)

## Key facts

- **NCT ID:** NCT05435053
- **Lead sponsor:** Ismail Gögenur
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-08
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included patients of which 2 of the patients were excluded before receiving any study treatments, thus 7 patients were treated in the study.
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435053, "Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05435053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*